| Document |
Document Title |
|
WO/2020/229014A1 |
The invention concerns a compound of Formula (I) or a salt thereof, wherein R1 is H, (C1-C3)alkyl or CF3; R2 is H, (C1-C3)alkyl or CF3; A is CH2COOH, XCH2COOCH2CH3, XCH2COOH, XCH2CH2NH2, where X is nitrogen or oxygen atom; Ar is an aroma...
|
|
WO/2020/228436A1 |
The present invention relates to aromatic ring or heteroaromatic ring derivatives, a preparation method therefor and applications thereof in medicine. Specifically, the present invention relates to aromatic ring or heteroaromatic ring de...
|
|
WO/2020/226522A1 |
The present invention falls within the area of the synthesis of ionic liquids, namely it concerns a process of synthesis of the ionic liquid tetraoctylammonium di(2-ethylhexyl)-oxamate (IL-5) with a high degree of purity and its use in t...
|
|
WO/2020/221690A1 |
The invention relates to a method for producing urea, comprising: a) producing formamide on the basis of carbon dioxide, hydrogen and ammonia, wherein methyl formate or ammonium formate is formed as an intermediate product in a catalytic...
|
|
WO/2020/222171A1 |
Herein is described an ionic complex catalyst and a process for olefin oligomerization of C14–C24 normal alpha olefins utilizing the ionic complex catalyst.
|
|
WO/2020/212993A1 |
Described herein are methods of enhancing formation and/or growth of an adventitious root in a plant and/or plant tissue, and/or for promoting grafting unification, enhancing fruit size and/or reducing flowering in a plant. The method co...
|
|
WO/2020/210914A1 |
The invention relates to compounds for use in imaging and/or for the diagnosis of conditions or diseases associated with an altered level of Neprilysin (NEP/CD10) in a subject having, or suspected of having said conditions or diseases. I...
|
|
WO/2020/207129A1 |
Disclosed is an ammonium salt with a structural formula represented by formula (I). A synthesis method thereof comprises using 8 mol% zinc chloride as a catalyst, 5 mmol of 1-phenyl-1,3-butanedione, 1.2 g of benzylamine, and 40 mL of chl...
|
|
WO/2020/198939A1 |
The present invention provides a crystalline form A of 2,2-bis(4-fluorophenyl)-2-phenylacetamide. The crystalline form has good light stability, high temperature stability, and high humidity stability.
|
|
WO/2020/203248A1 |
Provided is a method for producing a 4-halogenobenzylamine derivative that includes bringing a 1-methylbenzylamine derivative represented by formula (1) into contact with a halogenating agent to effect halogenation in the presence of sul...
|
|
WO/2020/199757A1 |
The present invention relates to a sulfonylbenzamide derivative, a preparation method therefor, and a medical use thereof. Specifically, disclosed are a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvat...
|
|
WO/2020/205470A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2020/203594A1 |
Provided is a fluorene derivative represented by formula (1). (In the formula, Z1 and Z2 are predetermined divalent groups, and Ar1 and Ar2 are each independently a C6-20 aryl group or a C2-20 heteroaryl group, and may be substituted wit...
|
|
WO/2020/195576A1 |
Provided is a novel method for producing a hemiaminal compound, and a method for producing a heterocyclic compound. In this method for producing a hemiaminal compound, a compound represented by formula (1), a compound represented by form...
|
|
WO/2020/193419A1 |
The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
|
|
WO/2020/194237A1 |
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...
|
|
WO/2020/196553A1 |
The purpose of the present invention is to provide a method that enables efficient and safe production of an N-substituted trihaloacetamide which also serves as a synthetic intermediate for isocyanate compounds, carbamate compounds, urea...
|
|
WO/2020/187155A1 |
Use of an apocynin dimer analogue derivative in preparing a medicament or a health care product for preventing and treating Parkinson's disease. The structure of the apocynin dimer analogue derivative is as shown in formula I. The apocyn...
|
|
WO/2020/185420A1 |
Provided herein are integrated methods and systems for the production of acrylamide and acrylonitrile compounds and other compounds from at least beta-lactones and/or beta-hydroxy amides.
|
|
WO/2020/181779A1 |
A method for preparing a lipoamino acid compound on the basis of a deep eutectic solvent, which relates to the field of organic synthesis. A fatty acid and an amino acid are used as substrates and a deep eutectic solvent is used as a med...
|
|
WO/2020/183281A1 |
This invention provides for a flow synthesis process for producing Oseltamivir and pharmaceutically acceptable salts thereof from shikimic acid in particular but not exclusively to a flow synthesis process for producing Oseltamivir phosp...
|
|
WO/2020/172749A1 |
Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as metho...
|
|
WO/2020/169054A1 |
The present invention relates to crystalline forms I and II of a (E)-α,β-unsatured amide compound, preparation methods therefor, and uses thereof. The crystalline forms all have excellent properties in physical and chemical stability a...
|
|
WO/2020/168385A1 |
The present invention relates to a method of preparing N-acyl amino acids selected from N-acyl cysteine compounds, N-acyl serine compounds, N-acyl aspartic acid compounds and N-acyl glutamic acid compounds. The present invention also rel...
|
|
WO/2020/171210A1 |
The phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. The problem, however, is the amount ingested to inhibit cancer cell growth is large. A cancer cell growth inhibiting composition having...
|
|
WO/2020/167855A1 |
Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cance...
|
|
WO/2020/168152A2 |
Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selec...
|
|
WO/2020/161743A1 |
The present disclosure relates to an improved process for the preparation of bedaquiline fumarate, comprising a step of preparing bedaquiline by reaction of 3-benzyl-6-bromo-2-methoxyquinoline 5 with 3-(dimethylamino)-l-(naphthalen-l-yl)...
|
|
WO/2020/161275A1 |
The present invention relates to novel, optionally substituted, N-benzyl-2- phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmac...
|
|
WO/2020/159797A1 |
Compounds and compositions including stereoisomers of 6-phenylhexanamide derivative small molecule mitofusin activators are described. In particular, mitofusin activators comprising derivatives of (trans-4-hydroxylcyclohexyl)-6-phenylhex...
|
|
WO/2020/157126A1 |
The present invention relates to a class of novel compounds of general formula (I), their use as medicaments and pharmaceutical compositions comprising them. Specifically, the compounds of the invention are useful as voltage-gated potass...
|
|
WO/2020/157189A1 |
The present invention includes name compounds of general formula (I) in which R1, Y, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical composi...
|
|
WO/2020/156312A1 |
The present invention relates to a polycyclic derivative modulator, a preparation method therefor and an application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation me...
|
|
WO/2020/159167A1 |
The present invention provides a method for recovering amide-based compounds, wherein, before a distillation step for separating and recovering amide-based compounds from waste liquid including amide-based compounds such as N-methyl-2-py...
|
|
WO/2020/160464A1 |
A TRPM8 antagonist is provided that comprises the following the formula (I) described herein. In the formula (I), R1 is selected from a cycloalkyl, a bicycloalkyl, or a tricycloalkyl group. Each R1 group has 5 to 12 carbon atoms. Further...
|
|
WO/2020/116589A9 |
The purpose of the present disclosure is to provide a novel method for producing a fluorovinyl amide compound. The purpose is achieved by means of a method for producing a compound represented by formula (I) [in the formula, Rf is -F or ...
|
|
WO/2020/152226A1 |
The present invention relates to a polymorphic form of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl- 4-hydroxybenzene)-3-phenylpropylamide or synonymously named N-[2-(4-Hydroxy-phenyl)- -(2-hydroxy-propoxymethyl)-ethyl]-3-phenyl-propionamide and...
|
|
WO/2020/147582A1 |
Provided are an amide derivative substituted by cycloalkyl, a preparation method for the amide derivative, and a use in medicine. Specifically, provided are a compound of formula (I), or a pharmaceutically acceptable salt or stereisomer ...
|
|
WO/2020/149129A1 |
The purpose of the present invention is to produce an asymmetric compound from an oxalyl halide in a simple manner and with high selectivity. The method comprises: a first step of mixing a first raw material selected from ammonia, a mo...
|
|
WO/2020/148760A1 |
The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.
|
|
WO/2020/146771A1 |
The present application provides anandamide and 2-arachidonyl glycerol compounds useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating disease...
|
|
WO/2020/142865A1 |
Disclosed in the present invention are a Benzamide compound, intermediates, a preparation method, and an application. The present invention provides a Benzamide compound as represented by formula I, and pharmaceutically acceptable salts,...
|
|
WO/2020/142745A1 |
The invention relates to treatment of graft versus host disease (GVHD) or neoplastic disease using compounds that inhibit Rho-associated protein kinases. In preferred aspects, the present invention provides methods for the treatment of c...
|
|
WO/2020/141927A1 |
The present specification relates to an adamantanecarboxylic acid benzyl amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, and a skin whitening composition c...
|
|
WO/2020/138011A1 |
The present invention addresses the problem of providing a compound which has a retinoic acid receptor agonist activity and is useful as a medicine that is capable of treating and/or preventing a retinal degenerative disease. The compoun...
|
|
WO/2020/137951A1 |
The present invention relates to: a composition for producing an N-vinyl carboxylic acid amide, the composition comprising component (A) which is an N-(1-alkoxy ethyl)carboxylic acid amide and component (B) which is an N-(1-alkoxy ethyl)...
|
|
WO/2020/135560A1 |
An acetylsalicylic acid derivative and an application thereof. The present invention relates to the field of chemical pharmaceuticals, and in particular, to a compound shown in formula (I) or pharmaceutically acceptable salts thereof. (I)
|
|
WO/2020/127237A1 |
N-acylglucamide compound of the formula (I) where R2 is a linear or branched alkyl group or an aryl group; X is a moiety R1, which is a linear or branched alkyl group comprising 8 to 18, carbon atoms, which is substituted by one hydroxy ...
|
|
WO/2020/123414A1 |
The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of ...
|
|
WO/2020/115753A1 |
The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L- DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar ...
|
